ULTRAGENYX PHARMACEUTICAL INC. Debt Securities, Available-for-sale, Current
ULTRAGENYX PHARMACEUTICAL INC. (RARE) had Debt Securities, Available-for-sale, Current of $167.00 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent · last filed 2026-08-05
- 2026-06-30: Debt Securities, Available-for-sale, Current $167.00M.
- 2026-03-31: Debt Securities, Available-for-sale, Current $238.00M.
- 2025-12-31: Debt Securities, Available-for-sale, Current $259.00M.
- 2025-09-30: Debt Securities, Available-for-sale, Current $222.74M.
| Period end | Debt Securities, Available-for-sale, Current | Debt Securities, Available-for-sale, Current as first filed |
|---|---|---|
| 2026-06-30 | $167.00M 10-Q · filed 2026-08-05 | |
| 2026-03-31 | $238.00M 10-Q · filed 2026-05-06 | |
| 2025-12-31 | $259.00M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $222.74M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | $311.28M 10-Q · filed 2025-08-06 | |
| 2025-03-31 | $367.38M 10-Q · filed 2025-05-07 | |
| 2024-12-31 | $436.00M 10-K · filed 2026-02-18 | $436.30M 10-K · filed 2025-02-19 |
| 2024-09-30 | $470.99M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $283.13M 10-Q · filed 2024-08-02 | |
| 2024-03-31 | $299.83M 10-Q · filed 2024-05-03 | |
| 2023-12-31 | $363.63M 10-K · filed 2025-02-19 | |
| 2023-09-30 | $369.52M 10-Q · filed 2023-11-03 | |
| 2023-06-30 | $449.92M 10-Q · filed 2023-08-04 | |
| 2023-03-31 | $543.59M 10-Q · filed 2023-05-05 | |
| 2022-12-31 | $614.82M 10-K · filed 2024-02-21 | |
| 2022-09-30 | $497.02M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $382.93M 10-Q · filed 2022-07-29 | |
| 2022-03-31 | $444.33M 10-Q · filed 2022-05-06 | |
| 2021-12-31 | $432.61M 10-K · filed 2023-02-17 | |
| 2021-09-30 | $539.58M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | $554.88M 10-Q · filed 2021-08-03 | |
| 2021-03-31 | $581.61M 10-Q · filed 2021-05-05 | |
| 2020-12-31 | $488.01M 10-K · filed 2022-02-15 | |
| 2019-12-31 | $321.65M 10-K · filed 2021-02-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |